Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 4/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791207 | 0.79 | CTPS1 (0.40) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL22749305 | 0.78 | LMNA (0.36) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29368124 | 0.77 | LMNA (0.35) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28701070 | 0.77 | LMNA (0.35) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL22758556 | 0.77 | FFAR4 (0.39) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| Lithium SCHEMBL30725900 | 0.76 | FFAR4 (0.38) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL29142075 | 0.76 | FFAR4 (0.38) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL21392085 | 0.75 | FFAR4 (0.35) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| Lithium Ion SCHEMBL22749301 | 0.75 | FFAR4 (0.35) | LMNAALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL20137350 | 0.74 | LMNA (0.34) | LMNAALDH1A1GAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-4041723-A2 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041715-A1 | SULFONAMIDE INHIBITORS AS CTPS 1 INHIBITORS | Step Pharma S.A.S. (FR) | 2022-08-17 | — | — | EP | disclosed |
| EP-3980410-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Step Pharma S.A.S. (FR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021053403-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053402-A2 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | LMNA 2653/4885ALDH1A1 1517/4885GAA 974/4885 |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | LMNA 1330/4885ALDH1A1 2214/4885GAA 1324/4885 |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | LMNA 3170/4885ALDH1A1 978/4885GAA 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.